Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

Br J Cancer · 2010 · PMC2938266 · PMID 20733579

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP <0.001actually significant

There was a highly significant linear relationship between AUC 0− t and the total dose of CYT997 infused ( P <0.001; Figure 1A ), indicating that the pharmacokinetics of CYT997 were linear over the entire 50-fold dose range investigated in this study (7–358 mg m −2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.